[1] |
Coroneo MT, Di Girolamo N, Wakefteld D. The pathogenesis of pterygia[J]. Curt Opin Ophthalmol,1999,10:282-288.
|
[2] |
Gebhardt M, Mentlein R, Schaudig U, et al. Differential expression of vascular endothelial growth factor implies the limbal origin of pterygia[J]. Ophthalmology,2005,112:1023-1030.
|
[3] |
Gueudry J, Richez F, Tougeron-Brousseau B, et al. Subconjunctival bevacizumab for corneal neovascularization[J]. J Fr Ophthalmol,2010,33: 630-636.
|
[4] |
Dastjerdi MH, Al-Arfaj KM, Nallasamy N, et al. Topical bevacizumab in the treatment of corneal neovascularization:results of a prospective, open-label, noncomparative study[J]. Arch Ophthalmol,2009,127:381-389.
|
[5] |
Besharati MR, Manaviat MR, Souzani A. Subconjunctival bevacizumab injection in treatment of pterygium[J]. Acta Med Iran,2011,49:179-183.
|
[6] |
Enkvetchakul O, Thanathanee O, Rangsin R, et al. A randomized controlled trial of intralesional bevacizumab injection on primary pterygium: preliminary results[J]. Cornea,2011,30: 1213-1218.
|
[7] |
Lekhanont K, Patarakittam T, Thongphiew P, et al. Randomized controlled trial of subconjunctival bevacizumab injection in impending recurrent pterygium: a pilot study[J]. Cornea,2012, 2:155-161.
|
[8] |
Shenasi A, Mousavi F, Shoa-Ahari S, et al. Subconjunctival bevacizumab immediately after excision of primary pterygium: the first clinical trial[J]. Cornea,2011,30:1219-1222.
|
[9] |
Prabhasawat P, Barton K, Burkett G, et al. Comparison of conjunctival autografts, amniotic membrane grafts, and primary closure for pterygium excision[J]. Ophthalmology,1997,104:974-985.
|
[10] |
Hosseini H, Nejabat M, Khalili MR. Bevacizumab (Avastin) as a potential novel adjunct in the management of pterygia[J]. Med Hypotheses,2007,69:925-927.
|
[11] |
You IC, Kang IS, Lee SH, et al. Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization[J]. Acta Ophthalmol,2009,87:653-658.
|
[12] |
Doctor PP, Bhat PV, Foster CS. Subconjunctival bevacizumab for corneal neovascularization[J]. Cornea,2008,27:992-995.
|
[13] |
Razeghinejad MR, Hosseini H, Ahmadi F,et al. Preliminary results of subconjunctival bevacizumab in primary pterygium excision[J]. Ophthalmic Res,2010,43:134-138.
|
[14] |
Banifatemi M, Razeghinejad MR, Hosseini H, et al. Bevacizumab and ocular wound healing after primary pterygium excision[J]. J Ocul Pharmacol Ther,2011,27:17-21.
|
[15] |
Bhasin P, Gujar P, Bhasin P. A case of recipient bed melt and wound dehiscence after penetrating keratoplasty and subconjunctival injection of bevacizumab[J]. Cornea,2012,31:1342-1343.
|
[16] |
Calcagni M, Althaus MK, Knapik AD, et al. In vivo visualization of the origination of skin graft vasculature in a wild-type/GFP crossover model[J]. Microvasc Res,2011,82:237-245.
|
[17] |
Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium[J]. Curr Eye Res,2008,33:23-28.
|